JP2009500457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009500457A5 JP2009500457A5 JP2008521639A JP2008521639A JP2009500457A5 JP 2009500457 A5 JP2009500457 A5 JP 2009500457A5 JP 2008521639 A JP2008521639 A JP 2008521639A JP 2008521639 A JP2008521639 A JP 2008521639A JP 2009500457 A5 JP2009500457 A5 JP 2009500457A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- antibody
- composition according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 2
- 108010056243 alanylalanine Proteins 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010052015 cytokine release syndrome Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229960003611 pramlintide Drugs 0.000 claims 1
- 108010029667 pramlintide Proteins 0.000 claims 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69851705P | 2005-07-11 | 2005-07-11 | |
| PCT/US2006/027386 WO2007009064A2 (en) | 2005-07-11 | 2006-07-11 | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012154666A Division JP2013005798A (ja) | 2005-07-11 | 2012-07-10 | 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009500457A JP2009500457A (ja) | 2009-01-08 |
| JP2009500457A5 true JP2009500457A5 (https=) | 2009-08-27 |
Family
ID=37637980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521639A Pending JP2009500457A (ja) | 2005-07-11 | 2006-07-11 | 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法 |
| JP2012154666A Pending JP2013005798A (ja) | 2005-07-11 | 2012-07-10 | 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012154666A Pending JP2013005798A (ja) | 2005-07-11 | 2012-07-10 | 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8663634B2 (https=) |
| EP (2) | EP2497496A3 (https=) |
| JP (2) | JP2009500457A (https=) |
| AU (1) | AU2006267090B2 (https=) |
| CA (1) | CA2614640A1 (https=) |
| IL (1) | IL188592A (https=) |
| SG (3) | SG163615A1 (https=) |
| WO (1) | WO2007009064A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2007009064A2 (en) | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| CN101309703A (zh) * | 2005-09-12 | 2008-11-19 | 诺维莫尼公司 | 抗cd3抗体组合物 |
| EP2433650A3 (en) * | 2006-06-06 | 2012-12-19 | Tolerrx Inc. | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
| SG177907A1 (en) * | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| CA2673470A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US8795667B2 (en) * | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
| EP2260057B1 (en) * | 2008-03-13 | 2016-11-23 | Biotest AG | Anti-CD4 antibody dosage regimen for treating autoimmune disease |
| RU2540013C2 (ru) * | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
| EP2265643B1 (en) * | 2008-03-13 | 2016-10-19 | Biotest AG | Dosing regimen for treating psoriasis and rheumatoid arthritis |
| ES2589912T3 (es) | 2008-04-02 | 2016-11-17 | Macrogenics, Inc. | Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos |
| WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
| US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| BRPI0919489A2 (pt) * | 2008-09-29 | 2015-12-01 | Biotest Ag | composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato |
| WO2011047172A1 (en) * | 2009-10-14 | 2011-04-21 | Celtaxsys, Inc. | Method of treating inflammation |
| CA2778334A1 (en) * | 2009-10-20 | 2011-04-28 | Charlotte Mckee | Anti-cd3 antibody dosing in autoimmune disease |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2556161A4 (en) * | 2010-04-09 | 2013-11-06 | Gen Hospital Corp | METHOD FOR TREATING AUTOIMMUNE DISEASES |
| EP2585828A4 (en) * | 2010-06-25 | 2014-03-12 | Glaxo Group Ltd | METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP2015091761A (ja) * | 2012-02-23 | 2015-05-14 | 国立大学法人大阪大学 | 中枢神経の損傷を治療するための組成物およびその利用 |
| PT2850106T (pt) * | 2012-05-18 | 2022-07-18 | Aptevo Res & Development Llc | Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3 |
| EP2892924B1 (en) | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2013188693A1 (en) * | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| US9511110B2 (en) * | 2012-09-27 | 2016-12-06 | Perle Bioscience, Inc. | Generation of new pancreatic beta cells |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
| PL3129483T3 (pl) * | 2014-04-08 | 2019-05-31 | Fraunhofer Ges Forschung | Terapia skojarzona do leczenia chorób autoimmunologicznych |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP3430058A4 (en) | 2016-03-15 | 2019-10-23 | Generon (Shanghai) Corporation Ltd. | MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF |
| GEP20227398B (en) | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| CN109952112B (zh) | 2016-09-21 | 2024-09-06 | 阿帕特夫研究和发展有限公司 | Cd123结合蛋白和相关的组合物和方法 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP2021509812A (ja) | 2018-01-05 | 2021-04-08 | プレートレット バイオジェネシス， インコーポレイテッド | 巨核球を産生するための組成物および方法 |
| EP3813853A4 (en) | 2018-06-29 | 2022-04-06 | Platelet Biogenesis, Inc. | DELIVERY COMPOSITIONS AND METHODS OF USE |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
| WO2021195544A1 (en) * | 2020-03-27 | 2021-09-30 | Platelet Biogenesis, Inc. | Novel anucleated cells for the treatment of diseases |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CA3200998A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4493592A1 (en) | 2022-03-14 | 2025-01-22 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2024182767A1 (en) | 2023-03-01 | 2024-09-06 | Provention Bio, Inc. | Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil |
| TW202506177A (zh) | 2023-03-30 | 2025-02-16 | 美商普泛森生技公司 | 減少外源性胰島素使用之方法 |
| AU2024299422A1 (en) | 2023-07-27 | 2026-03-12 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| EP4574174A1 (en) * | 2023-12-19 | 2025-06-25 | Jack Elands | Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51133489A (en) * | 1975-05-14 | 1976-11-19 | Tokyo Daigaku | Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities |
| US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4515893A (en) * | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| US4658019A (en) * | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
| US4221794A (en) * | 1979-06-21 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | Method of imparting immunomodulating and antiviral activity |
| US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US4695624A (en) * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| NZ214503A (en) * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
| US5078998A (en) * | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4882424A (en) * | 1987-05-11 | 1989-11-21 | Dana-Farber Cancer Institute, Inc. | Activation antigen |
| CA2003455C (en) | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3485184B2 (ja) | 1989-07-14 | 2004-01-13 | アメリカン サイアナミド カンパニー | インターロイキン含有安定ワクチン組成物 |
| SE8903100D0 (sv) | 1989-09-20 | 1989-09-20 | Pharmacia Ab | New pharmaceutical agent |
| US6406696B1 (en) * | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| WO1991006319A1 (en) * | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ZA91463B (en) | 1990-01-25 | 1992-09-30 | Bristol Myers Squibb Co | Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody |
| EP0537293A4 (en) | 1990-07-02 | 1993-09-08 | Bristol-Myers Company | Ligand for cd28 receptor on b cells and methods |
| WO1992015671A1 (en) | 1991-03-08 | 1992-09-17 | Cytomed, Inc. | Soluble cd28 proteins and methods of treatment therewith |
| CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| EP1488805A2 (en) | 1992-04-07 | 2004-12-22 | The Regents of the University of Michigan | CD28 pathway immunoregulation |
| WO1993025712A1 (en) | 1992-06-15 | 1993-12-23 | The Regents Of The University Of California | Screening assay for the identification of immunosuppressive drugs |
| WO1994023760A1 (en) | 1993-04-14 | 1994-10-27 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
| CA2167091A1 (en) | 1993-07-26 | 1995-02-02 | Gordon J. Freeman | B7-2: ctl a4/cd 28 counter receptor |
| WO1998047531A2 (en) * | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US7041289B1 (en) * | 1997-12-05 | 2006-05-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for treating established spontaneous auto-immune diseases in mammals |
| AU7740600A (en) | 1999-10-01 | 2001-05-10 | Biotransplant Incorporated | Process for inducing functional tolerance to gene transfer products |
| GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
| US20030216551A1 (en) * | 2002-03-08 | 2003-11-20 | Diabetogen Biosciences Inc. | Fully human anti-CD3 monoclonal antibodies |
| WO2003102132A2 (en) * | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
| EP1515749B1 (en) | 2002-06-14 | 2012-08-15 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a glp-1 compound |
| WO2003105896A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a beta cell resting compound |
| CA2512729C (en) * | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7883703B2 (en) * | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| EP1725254A4 (en) * | 2004-02-04 | 2008-02-13 | Univ Columbia | ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| WO2007009064A2 (en) | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| EP2433650A3 (en) | 2006-06-06 | 2012-12-19 | Tolerrx Inc. | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
| CA2673470A1 (en) | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
-
2006
- 2006-07-11 WO PCT/US2006/027386 patent/WO2007009064A2/en not_active Ceased
- 2006-07-11 AU AU2006267090A patent/AU2006267090B2/en active Active
- 2006-07-11 CA CA002614640A patent/CA2614640A1/en not_active Abandoned
- 2006-07-11 US US11/485,557 patent/US8663634B2/en active Active
- 2006-07-11 EP EP12166907A patent/EP2497496A3/en not_active Withdrawn
- 2006-07-11 SG SG201005116-7A patent/SG163615A1/en unknown
- 2006-07-11 SG SG10201504917PA patent/SG10201504917PA/en unknown
- 2006-07-11 JP JP2008521639A patent/JP2009500457A/ja active Pending
- 2006-07-11 SG SG2011097946A patent/SG177944A1/en unknown
- 2006-07-11 EP EP06787311A patent/EP1904105A4/en not_active Ceased
-
2008
- 2008-01-03 IL IL188592A patent/IL188592A/en active IP Right Grant
-
2012
- 2012-07-10 JP JP2012154666A patent/JP2013005798A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009500457A5 (https=) | ||
| Kuhn et al. | Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside | |
| AU2009224690B2 (en) | Agent for treating disease | |
| JP4628792B2 (ja) | 免疫疾患治療用ラパマイシン及びｉｌ−１０ | |
| TWI373343B (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
| CA2718191C (en) | Agent for treating disease | |
| JP2009539841A5 (https=) | ||
| JP2009544761A5 (https=) | ||
| JP2020002172A5 (https=) | ||
| JP2013508392A5 (https=) | ||
| CA3176161A1 (en) | Anti-human vista antibodies and use thereof | |
| EP2119452B1 (en) | Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis | |
| CN115175935A (zh) | Cal-t构建体及其用途 | |
| JP6154847B2 (ja) | 疾患治療組成物 | |
| JP2022513421A5 (https=) | ||
| US20120308564A1 (en) | Treatment of a metabolic disorder | |
| WO2023164256A2 (en) | Regulatory t cells with chimeric antigen receptor targeting co-stimulatory molecules to prevent and/or treat inflammatory conditions | |
| AU2005232653B2 (en) | Methods of treating autoimmune and inflammatory diseases | |
| JP2009538916A5 (https=) | ||
| US12466877B2 (en) | Metallothionein antibodies and their use | |
| Rose et al. | Monoclonal antibody treatments for multiple sclerosis | |
| JP2013508391A5 (https=) | ||
| JP2005529152A5 (https=) | ||
| CN1291998C (zh) | Nkg2d受体的配体及其应用 | |
| Sardana et al. | Therapeutic trials for systemic sclerosis: An update |